{"id":"candin-intradermal-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reaction"},{"rate":null,"effect":"Hypersensitivity reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Candin contains heat-killed candida albicans organisms administered intradermally to provoke a therapeutic immune response. It is designed to enhance the body's own T-cell mediated immunity against candida, potentially treating or preventing candida-related conditions. The intradermal route allows direct presentation of candida antigens to the immune system.","oneSentence":"Candin is a candida albicans antigen preparation that stimulates delayed-type hypersensitivity and cell-mediated immune responses against candida infections.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:04:51.076Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Candida-related conditions (specific indication in Phase 3 development unclear)"}]},"trialDetails":[{"nctId":"NCT05889845","phase":"PHASE3","title":"Candin for the Treatment of Common Warts","status":"COMPLETED","sponsor":"Nielsen BioSciences, Inc.","startDate":"2025-01-22","conditions":"Common Warts (Verruca Vulgaris)","enrollment":330},{"nctId":"NCT05952934","phase":"PHASE2","title":"Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence","status":"RECRUITING","sponsor":"University of Arkansas","startDate":"2024-02-12","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":100},{"nctId":"NCT03953196","phase":"EARLY_PHASE1","title":"A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-04-08","conditions":"Healthy","enrollment":48},{"nctId":"NCT03158168","phase":"PHASE3","title":"Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-03-01","conditions":"Warts","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Candin, Intradermal Solution","genericName":"Candin, Intradermal Solution","companyName":"Nielsen BioSciences, Inc.","companyId":"nielsen-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Candin is a candida albicans antigen preparation that stimulates delayed-type hypersensitivity and cell-mediated immune responses against candida infections. Used for Candida-related conditions (specific indication in Phase 3 development unclear).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}